Moolec Science Granted Continued Listing on Nasdaq Subject to Hearings Panel Conditions
Moolec Science (NASDAQ: MLEC) was granted continued listing by a Nasdaq Hearings Panel, subject to specific conditions and timelines.
Rhea-AI Summary
Moolec Science (NASDAQ: MLEC) was granted continued listing by a Nasdaq Hearings Panel, subject to specific conditions and timelines. The Panel acknowledged bid-price compliance effective January 16, 2026, after a January 5, 2026 reverse stock split.
The Panel retained jurisdiction through May 13, 2026 and noted the company filed its Form 20-F for year-ended June 30, 2025 on December 29, 2025. Conditions include updates on derecognition by end-February 2026, pro forma financials by end-March 2026, public disclosure of compliance actions by May 13, 2026, and demonstration of full compliance by May 13, 2026.
Positive
- Bid-price compliance achieved on Jan 16, 2026
- Form 20-F filed on Dec 29, 2025
- Panel accepted a plan to regain equity compliance
Negative
- Continued listing remains conditional through May 13, 2026
- Must deliver pro forma financials by end of March 2026
- Required updates on derecognition proceedings by end-Feb 2026
Details
News Market Reaction – MLEC
In the Feb 2 session, MLEC declined 17.38%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Listing rule
- Nasdaq Listing Rule 5550(b)(2)
- Minimum bid price compliance standard referenced by Panel
- Equity rule
- Nasdaq Listing Rule 5550(b)(1)
- Minimum stockholders’ equity requirement cited by Panel
- Reverse split date
- January 5, 2026
- Effective date of reverse stock split used to regain bid-price compliance
- Bid-price compliance date
- January 16, 2026
- Date Panel acknowledged minimum bid price compliance
- Panel jurisdiction end
- May 13, 2026
- Date through which Panel retains jurisdiction over bid-price matter
- Form 20-F filing date
- December 29, 2025
- Filing date for Annual Report for year ended June 30, 2025
- Update deadline
- End of February 2026
- Deadline to update Panel on derecognition proceedings
- Pro forma deadline
- End of March 2026
- Deadline to deliver updated pro forma financial information
Historical Context
-
Nasdaq Staff memo supporting exception through June 29, 2026 on equity rule.
-
Panel grants exception to regain stockholders’ equity compliance by June 29, 2026.
-
15-for-1 share consolidation becomes effective and reflected in trading quotes.
-
Nasdaq letter citing failure to meet $2.5M stockholders’ equity and net income rules.
-
Announcement of 15-for-1 consolidation plan intended to restore minimum bid price.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq hearings panel regulatory
reverse stock split financial
form 20-f regulatory
nasdaq capital market regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
GEORGE TOWN, CAYMAN ISLANDS / ACCESS Newswire / January 30, 2026 / Moolec Science S.A. ("Moolec" or the "Company"), a science-based food ingredient company focused on scalable protein solutions for the global market, today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing on The Nasdaq Stock Market, subject to certain conditions.
The Panel acknowledged that the Company satisfied the minimum bid price compliance period under Nasdaq Listing Rule 5550(b)(2) on January 16, 2026, following the effectiveness of its reverse stock split on January 5, 2026. The Panel will retain jurisdiction over the bid price matter through May 13, 2026, in accordance with its discretionary authority.
The Panel also noted that the Company filed its Annual Report on Form 20-F for the fiscal year ended June 30, 2025 on December 29, 2025, shortly following the hearing held on December 18, 2025.
With respect to the minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1), the Panel recognized that the Company has presented a plan that offers a reasonable expectation of regaining compliance within the applicable period.
The continued listing determination is subject to the Company satisfying certain conditions, including (i) the provision of updates to the Panel regarding the status of derecognition proceedings by the end of February 2026, (ii) the delivery of updated pro forma financial information by the end of March 2026, (iii) the timely public disclosure of actions taken to demonstrate compliance with Nasdaq's equity and continued listing requirements by May 13, 2026 and (iv) the Company's demonstration, on or before May 13, 2026, of compliance with all continued listing requirements for the Nasdaq Capital Market.
Moolec intends to fully satisfy the conditions outlined in the Panel's decision and remains focused on maintaining sustained compliance with Nasdaq's continued listing standards, strengthening its financial framework and advancing its strategic priorities.
About Moolec Science SA
Moolec Science is an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food system. By integrating Molecular Farming and precision fermentation, Moolec combines the cost efficiency of crops with the functionality and nutrition of animal proteins, creating sustainable and commercially viable ingredients. The Company's diversified pipeline includes alternative proteins, bioactive compounds, nutritional oils, and biological inputs for regenerative agriculture. Moolec has a robust intellectual property portfolio with more than 118 granted and pending patents across multiple technology platforms. With operations spanning the United States, Europe and South America, Moolec is advancing a seed-to-ingredient approach designed to transform the future of food production. Moolec is publicly listed on Nasdaq under the ticker "MLEC." For more information, please visit www.moolecscience.com and ir.moolecscience.com.
Forward-looking Statements
This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to the Company's plan to regain compliance under the Nasdaq rules, performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.
Contact: ir@moolecscience.com (+5493412034927)
SOURCE: Moolec Science
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.